Dr Jennifer Brown speaks to ecancer about the results from the phase 3 AMPLIFY trial presented at ASH 2024. This trial evaluated fixed-duration acalabrutinib plus venetoclax with or without obinutuzumab versus chemoimmunotherapy for first-line treatment of chronic lymphocytic leukaemia (CLL)

She reports that the estimated BICR-assessed three year progression-free survival of acalabrutinib plus venetoclax was 76% compared with 66% for chemoimmunotherapy.

Dr Brown also highlights the progression-free survival of acalabrutinib plus venetoclax and obinutuzumab which was 83%.